ASX Announcements 2010 ASX Announcements 2009 ASX Announcements 2008 ASX Announcements 2007 ASX Announcements 2006 ASX Announcements 2005 ASX Announcements 2004 ASX Announcements 2003 ASX Announcements 2002 Should you wish to view the report in your browser, you will need to have the Acrobat Reader installed. Please click on the icon (right) and follow the instructions. ASX Announcements 2008 ATL1103 Development on Schedule 17/12/2008   New Appointment to support the ATL/TV1102 Licensing Program 09/12/2008   ATL1101 intellectual property portfolio strengthened 19/11/2008   Change of Director's Interest Notice 06/11/2008   Change of Director's Interest Notice 05/11/2008   Annual General Meeting Results 31/10/2008   Annual General Meeting Presentation 31/10/2008   ANP To Present at Rodmand & Renshaw Healthcare Conference 28/10/2008   ATL1101 Preclinical Data in Prostate Cancer-US Presentation 17/10/2008   ATL1101 suppresses tumours in prostate cancer animal study 15/10/2008   Appendix 4C - Quarterly Cashflow Report 14/10/2008   Notice of AGM 24/09/2008   ANP and Isis Investor Conference Call Webcast 22/09/2008   Teva Pharmaceuticals Announcement re MS World Congress 16/09/2008   Investor Presentation 10/09/2008   ATL/TV1102 data to be presented at MS Scientific Meeting 28/08/2008   Results of General Meeting 26/08/2008   Preliminary Final Report - Appendix 4E 13/08/2008   Market Update 05/08/2008   Key Journal highlights IGF-1R as high interest cancer target 31/07/2008   Market Update 23/07/2008   Notice of Meeting Clarification 22/07/2008   Notice of Meeting 22/07/2008   Business and Strategy Update 21/07/2008   Phase IIa MS Trial Success - Teva to continue development 30/06/2008   ANP to present to Isis Shareholders in the US 02/06/2008   ATL1103 on Path to Clinic with Start of Toxicology Studies 06/05/2008   Notice under Section 708A(5)(e) 18/04/2008   ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial 17/04/2008   Placement 16/04/2008   Appendix 4C - Quarterly Cashflow Report 08/04/2008   ATL1102 Phase IIa MS Trial Update 01/04/2008   Research Director Receives 2008 Advancing BioBusiness Award 26/03/2008   Final Director's Interest Notice 17/03/2008   Resignation of Non-Excecutive Director 06/03/2008   ANP to Present at US Investor Conference 22/02/2008   ATL1102 Licensed to Teva Pharmaceutical Industries Ltd 11/02/2008   Market Update - MS Drug Tysabri Sales 07/02/2008   Appendix 4D Half Yearly Report Dec 2007 05/02/2008   Appendix 4C - Quarterly Cash Flow report 23/01/2008   Market Update 08/01/2008